http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 Jul 2026 16:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CREATIVE+MEDICAL+TECHNOL++For%3A+Aug+28/26768125.html si-local-file:///var/storage/secattach/20260714/26768125.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CREATIVE+MEDICAL+TECHNOL++For%3A+Aug+28/26768125.html Tue, 14 Jul 2026 16:00:00 -0400 CELZ O.07026615 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CREATIVE+MEDICAL+TECHNOL++For%3A+Aug+28/26768125.html si-local-file:///var/storage/secattach/20260714/26768125.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++CREATIVE+MEDICAL+TECHNOL++For%3A+Aug+28/26768125.html Tue, 14 Jul 2026 16:00:00 -0400 CELZ O.07026615 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CREATIVE+MEDICAL+TECHNOL++For%3A+Jun+30/26727982.html si-local-file:///var/storage/secattach/20260702/26727982.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CREATIVE+MEDICAL+TECHNOL++For%3A+Jun+30/26727982.html Thu, 02 Jul 2026 16:16:00 -0400 CELZ O.07026615 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CREATIVE+MEDICAL+TECHNOL++For%3A+Jun+30/26727982.html si-local-file:///var/storage/secattach/20260702/26727982.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CREATIVE+MEDICAL+TECHNOL++For%3A+Jun+30/26727982.html Thu, 02 Jul 2026 16:16:00 -0400 CELZ O.07026615 http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++CREATIVE+MEDICAL+TECHNOL++For%3A+Jul+01/26720627.html si-local-file:///var/storage/secattach/20260701/26720627.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++CREATIVE+MEDICAL+TECHNOL++For%3A+Jul+01/26720627.html Wed, 01 Jul 2026 16:06:00 -0400 CELZ O.07026615 http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++CREATIVE+MEDICAL+TECHNOL++For%3A+Jul+01/26720627.html si-local-file:///var/storage/secattach/20260701/26720627.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++CREATIVE+MEDICAL+TECHNOL++For%3A+Jul+01/26720627.html Wed, 01 Jul 2026 16:06:00 -0400 CELZ O.07026615 http://www.streetinsider.com/Guidance/Creative+Medical+Technology+issues+mid-year+pipeline+update/26717796.html <p>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) issued a mid-year update from CEO Timothy Warbington on July 1, 2026, outlining clinical and regulatory progress across its three core programs.</p><p>The company's lead candidate, Olastrocel (CELZ-201), is being evaluated in the FDA-cleared ADAPT trial for chronic lower back pain associated with degenerative disc disease. Interim blinded 180-day data reported in January showed statistically significant improvements in disability and pain, with no serious adverse events confirmed by an independent Data Safety Monitoring Board. In June, the FDA cleared an expansion of the trial to enroll patients receiving less than 90 mg per day http://www.streetinsider.com/Guidance/Creative+Medical+Technology+issues+mid-year+pipeline+update/26717796.html Wed, 01 Jul 2026 09:01:12 -0400 CELZ http://www.streetinsider.com/Corporate+News/Creative+Medical+Technology+issues+mid-year+pipeline+update/26717796.html <p>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) issued a mid-year update from CEO Timothy Warbington on July 1, 2026, outlining clinical and regulatory progress across its three core programs.</p><p>The company's lead candidate, Olastrocel (CELZ-201), is being evaluated in the FDA-cleared ADAPT trial for chronic lower back pain associated with degenerative disc disease. Interim blinded 180-day data reported in January showed statistically significant improvements in disability and pain, with no serious adverse events confirmed by an independent Data Safety Monitoring Board. In June, the FDA cleared an expansion of the trial to enroll patients receiving less than 90 mg per day http://www.streetinsider.com/Corporate+News/Creative+Medical+Technology+issues+mid-year+pipeline+update/26717796.html Wed, 01 Jul 2026 09:01:12 -0400 CELZ http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html <p align="left">PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today issued a mid-year update from Timothy Warbington, President and CEO.</p> <p>Dear Fellow Shareholder:</p> <p>Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis (“OA”), immunotherapy, and biodefense.</p> http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html Wed, 01 Jul 2026 09:00:00 -0400 A.17568957 A.18970468 CELZ O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html <p align="left">PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today issued a mid-year update from Timothy Warbington, President and CEO.</p> <p>Dear Fellow Shareholder:</p> <p>Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis (“OA”), immunotherapy, and biodefense.</p> http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html Wed, 01 Jul 2026 09:00:00 -0400 A.17568957 A.18970468 CELZ O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html <p align="left">PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today issued a mid-year update from Timothy Warbington, President and CEO.</p> <p>Dear Fellow Shareholder:</p> <p>Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis (“OA”), immunotherapy, and biodefense.</p> http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html Wed, 01 Jul 2026 09:00:00 -0400 A.17568957 A.18970468 CELZ O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html <p align="left">PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today issued a mid-year update from Timothy Warbington, President and CEO.</p> <p>Dear Fellow Shareholder:</p> <p>Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis (“OA”), immunotherapy, and biodefense.</p> http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html Wed, 01 Jul 2026 09:00:00 -0400 A.17568957 A.18970468 CELZ O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html <p align="left">PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today issued a mid-year update from Timothy Warbington, President and CEO.</p> <p>Dear Fellow Shareholder:</p> <p>Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis (“OA”), immunotherapy, and biodefense.</p> http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html Wed, 01 Jul 2026 09:00:00 -0400 A.17568957 A.18970468 CELZ O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html <p align="left">PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today issued a mid-year update from Timothy Warbington, President and CEO.</p> <p>Dear Fellow Shareholder:</p> <p>Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis (“OA”), immunotherapy, and biodefense.</p> http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html Wed, 01 Jul 2026 09:00:00 -0400 A.17568957 A.18970468 CELZ O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html <p align="left">PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today issued a mid-year update from Timothy Warbington, President and CEO.</p> <p>Dear Fellow Shareholder:</p> <p>Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis (“OA”), immunotherapy, and biodefense.</p> http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html Wed, 01 Jul 2026 09:00:00 -0400 A.17568957 A.18970468 CELZ O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html <p align="left">PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today issued a mid-year update from Timothy Warbington, President and CEO.</p> <p>Dear Fellow Shareholder:</p> <p>Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis (“OA”), immunotherapy, and biodefense.</p> http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html Wed, 01 Jul 2026 09:00:00 -0400 A.17568957 A.18970468 CELZ O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html <p align="left">PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today issued a mid-year update from Timothy Warbington, President and CEO.</p> <p>Dear Fellow Shareholder:</p> <p>Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis (“OA”), immunotherapy, and biodefense.</p> http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html Wed, 01 Jul 2026 09:00:00 -0400 A.17568957 A.18970468 CELZ O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html <p align="left">PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today issued a mid-year update from Timothy Warbington, President and CEO.</p> <p>Dear Fellow Shareholder:</p> <p>Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis (“OA”), immunotherapy, and biodefense.</p> http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html Wed, 01 Jul 2026 09:00:00 -0400 A.17568957 A.18970468 CELZ O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html <p align="left">PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today issued a mid-year update from Timothy Warbington, President and CEO.</p> <p>Dear Fellow Shareholder:</p> <p>Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis (“OA”), immunotherapy, and biodefense.</p> http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html Wed, 01 Jul 2026 09:00:00 -0400 A.17568957 A.18970468 CELZ O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html <p align="left">PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”)</strong>, a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today issued a mid-year update from Timothy Warbington, President and CEO.</p> <p>Dear Fellow Shareholder:</p> <p>Creative Medical has entered the second half of 2026 with a strengthened clinical, regulatory, and strategic position across its core programs in chronic lower back pain, osteoarthritis (“OA”), immunotherapy, and biodefense.</p> http://www.streetinsider.com/Globe+Newswire/Creative+Medical+Technology+Holdings+Issues+Mid-Year+Update/26717743.html Wed, 01 Jul 2026 09:00:00 -0400 A.17568957 A.18970468 CELZ O.04889877 O.07026615 O.36684209 http://www.streetinsider.com/Corporate+News/Creative+Medical+Technology+Holdings+raises+%244.5M+via+warrant+exercise/26712709.html <p>Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced agreements with certain warrant holders for the immediate exercise of outstanding warrants to purchase up to 2,790,340 shares of common stock at a reduced exercise price of $1.60 per share.</p><p>The warrants were originally issued in October 2025. The aggregate gross proceeds from the exercise are expected to total approximately $4.5 million, before deducting financial advisory fees. The transaction was expected to close on June 30, 2026.</p><p>In exchange for the immediate cash exercise of the existing warrants, the company will issue new unregistered warrants to purchase up to 5,580,680 shares of common stock http://www.streetinsider.com/Corporate+News/Creative+Medical+Technology+Holdings+raises+%244.5M+via+warrant+exercise/26712709.html Tue, 30 Jun 2026 14:08:18 -0400 CELZ http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Announces+Agreements+for+Exercise+of+Warrants+for+%244.5+Million+Gross+Proceeds/26712706.html <p align="justify">PHOENIX, June 30, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc.</strong>, (Nasdaq: CELZ) (the “Company”), a biotechnology company dedicated to the advancement of regenerative therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedic, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 2,790,340 shares of common stock of the Company originally issued in October 2025, at a reduced exercise price of $1.60 per share. The shares of common stock issuable upon exercise of the http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Announces+Agreements+for+Exercise+of+Warrants+for+%244.5+Million+Gross+Proceeds/26712706.html Tue, 30 Jun 2026 14:07:00 -0400 A.01857600 A.18970468 CELZ O.00080482 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Announces+Agreements+for+Exercise+of+Warrants+for+%244.5+Million+Gross+Proceeds/26712706.html <p align="justify">PHOENIX, June 30, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc.</strong>, (Nasdaq: CELZ) (the “Company”), a biotechnology company dedicated to the advancement of regenerative therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedic, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 2,790,340 shares of common stock of the Company originally issued in October 2025, at a reduced exercise price of $1.60 per share. The shares of common stock issuable upon exercise of the http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Announces+Agreements+for+Exercise+of+Warrants+for+%244.5+Million+Gross+Proceeds/26712706.html Tue, 30 Jun 2026 14:07:00 -0400 A.01857600 A.18970468 CELZ O.00080482 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Announces+Agreements+for+Exercise+of+Warrants+for+%244.5+Million+Gross+Proceeds/26712706.html <p align="justify">PHOENIX, June 30, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc.</strong>, (Nasdaq: CELZ) (the “Company”), a biotechnology company dedicated to the advancement of regenerative therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedic, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 2,790,340 shares of common stock of the Company originally issued in October 2025, at a reduced exercise price of $1.60 per share. The shares of common stock issuable upon exercise of the http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Announces+Agreements+for+Exercise+of+Warrants+for+%244.5+Million+Gross+Proceeds/26712706.html Tue, 30 Jun 2026 14:07:00 -0400 A.01857600 A.18970468 CELZ O.00080482 O.07026615 O.36684209 http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Announces+Agreements+for+Exercise+of+Warrants+for+%244.5+Million+Gross+Proceeds/26712706.html <p align="justify">PHOENIX, June 30, 2026 (GLOBE NEWSWIRE) -- <strong>Creative Medical Technology Holdings, Inc.</strong>, (Nasdaq: CELZ) (the “Company”), a biotechnology company dedicated to the advancement of regenerative therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedic, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 2,790,340 shares of common stock of the Company originally issued in October 2025, at a reduced exercise price of $1.60 per share. The shares of common stock issuable upon exercise of the http://www.streetinsider.com/Press+Releases/Creative+Medical+Technology+Holdings+Announces+Agreements+for+Exercise+of+Warrants+for+%244.5+Million+Gross+Proceeds/26712706.html Tue, 30 Jun 2026 14:07:00 -0400 A.01857600 A.18970468 CELZ O.00080482 O.07026615 O.36684209